

Antiemetic premedication use in $\geq 5\%$ of patients in any treatment group in SPOTLIGHT and GLOW (FAS)^{a,b,c}

Medication ^d , n (%)	SPOTLIGHT		GLOW	
	Zolbetuximab + mFOLFOX6 (n = 283)	mFOLFOX6 + placebo (n = 282)	Zolbetuximab + CAPOX (n = 254)	Placebo + CAPOX (n = 253)
Aprepitant	126 (44.5)	100 (35.5)	105 (41.3)	107 (42.3)
Chlorphenamine	17 (6.0)	6 (2.1)	17 (6.7)	12 (4.7)
Chlorphenamine maleate	31 (11.0)	25 (8.9)	18 (7.1)	10 (4.0)
Dexamethasone	137 (48.4)	108 (38.3)	85 (33.5)	59 (23.3)
Dexamethasone sodium phosphate	54 (19.1)	40 (14.2)	38 (15.0)	42 (16.6)
Dexchlorpheniramine maleate	12 (4.2)	14 (5.0)	11 (4.3)	11 (4.3)
Diphenhydramine hydrochloride	15 (5.3)	9 (3.2)	9 (3.5)	3 (1.2)
Famotidine	27 (9.5)	6 (2.1)	16 (6.3)	16 (6.3)
Fosaprepitant	65 (23.0)	64 (22.7)	34 (13.4)	24 (9.5)
Fosaprepitant meglumine	39 (13.8)	38 (13.5)	34 (13.4)	17 (6.7)
Granisetron	27 (9.5)	26 (9.2)	33 (13.0)	35 (13.8)
Granisetron hydrochloride	11 (3.9)	14 (5.0)	25 (9.8)	23 (9.1)
Lorazepam	23 (8.1)	27 (9.6)	14 (5.5)	14 (5.5)
Metoclopramide	15 (5.3)	8 (2.8)	23 (9.1)	17 (6.7)
Metoclopramide Dihydrochloride	3 (1.1)	3 (1.1)	17 (6.7)	12 (4.7)
Metoclopramide hydrochloride	30 (10.6)	27 (9.6)	28 (11.0)	14 (5.5)
Netupitant; palonosetron	18 (6.4)	15 (5.3)	5 (2.0)	2 (0.8)
Netupitant; palonosetron hydrochloride	29 (10.2)	32 (11.3)	12 (4.7)	9 (3.6)
Ondansetron	100 (35.3)	96 (34.0)	59 (23.2)	48 (19.0)

Ondansetron hydrochloride	23 (8.1)	21 (7.4)	18 (7.1)	21 (8.3)
Palonosetron	54 (19.1)	59 (20.9)	39 (15.4)	41 (16.2)
Palonosetron hydrochloride	91 (32.2)	85 (30.1)	79 (31.1)	74 (29.2)
Tropisetron hydrochloride	7 (2.5)	5 (1.8)	20 (7.9)	10 (4.0)

^aMedications used on the date of first dosing or later and continued while study drug was given are shown.

^bFAS included all randomized patients.

^cData cutoff date was 08 Sep 2023 for SPOTLIGHT and 12 Jan 2024 for GLOW.

^dActive ingredients for combination drugs.